SOURCE-LINKED STUDY SUMMARY
Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.
Full paper summarizedQuality not appraised
- What was studied
- This randomized placebo-controlled trial tested whether tesamorelin altered insulin response or diabetes control in people with type 2 diabetes.
- Who / model studied
- The 12-week study included 53 patients with type 2 diabetes; 16 received placebo, 18 received 1 mg and 19 received 2 mg.
- Studied dose & schedule
- Participants received placebo, tesamorelin 1 mg or tesamorelin 2 mg by subcutaneous injection for 12 weeks, followed by four weeks of adverse-event monitoring.
- What the study found
- Insulin response, fasting glucose, HbA1c and overall diabetes control did not differ significantly among groups at week 12. No participant discontinued because of lost diabetes control.
- Limitations & context
- The study was small and short, mostly enrolled White participants, did not objectively measure diet or exercise, and could not establish long-term safety.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1371/journal.pone.0179538